Transtek Medical Announces 2024 Annual Results: Strong Growth Across Revenue and Profit

ZHONGSHAN, China - Rezul -- On March 28, 2025, Transtek Medical(stock code: [300562.SZ]) announced its 2024 annual results, reporting solid growth across key financial metrics. For the reporting period, Transtek achieved revenue of RMB 984 million, representing an 11.28% year-on-year increase. Net profit attributable to shareholders rose sharply by 78.55% to RMB 61.36 million. The company's overall gross margin improved to 35.07%, up 4.13 percentage points from the previous year.

Throughout 2024, Transtek continued to advance its strategic positioning as a provider of medical-grade remote health monitoring devices and services. The company expanded its chronic disease management product portfolio, including smart blood pressure monitors, medical-grade ECG vests, blood glucose meters, body composition scales, OTC hearing aids, and smart wearables. These devices cover key health parameters such as blood pressure, blood glucose, body composition, PPG, ECG, physical activity, sleep, atrial fibrillation, and arrhythmias, and have obtained medical certifications across China, the U.S., Europe, and South Korea.

More on Rezul News

• Mike Wilen Launches Wilen Real Estate, NONMLS.com, and In-House Marketing Agency
• Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
• Transforming Vacant Lots into Vibrant Communities: A Seller's Guide to Empowering Growth
• Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
• Revolutionizing HOA Construction Services: ACCU, Inc. Launches Comprehensive Resource for Community Boards

In product development, Transtek made strategic progress in smart blood glucose monitoring, with products registered with the U.S. FDA and listed by SIGIS. Its subsidiary focusing on remote ECG services secured approval for the iSENSE 12-lead smart ECG vest as a Class II medical device.

Leveraging technological innovation, Transtek launched an AI-driven cardiovascular health model, integrating smart monitoring devices with AI healthcare services to deliver inclusive digital chronic disease management.

Looking forward, Transtek will continue to enrich its medical-grade product lineup, strengthen its technological leadership, and deepen its presence in global markets. The company remains committed to driving high-quality growth and expanding its role in the digital health ecosystem.

Founded in 2000, Transtek is committed to multiple health fields such as remote health and chronic disease management, providing customers with medical-grade "RPM devices" and "cloud services". Transtek also provides one-stop connectivity technology, device management, and fulfillment services for Remote Patient Monitoring (RPM) providers. Transtek has established a co-branded solution named TeleRPM since 2019, it stands for Quality & Value which is the best of Transtek. TeleRPM is an integrated solution which includes cellular blood pressure monitor, cellular weight scale, cellular blood glucose meter and all-round BLE package with AnyHub solution. Also, TeleRPM is open and scalable, and Transtek will leverage their expertise to help customers realize greater value, potential and outcomes.

More on Rezul News

• OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
• Mesa West Capital Funds $45 Million Loan for Acquisition of Embassy Suites Nashville at Vanderbilt
• Innovative Architect Firm in Boulder Pops in Luxury Home Design Market
• Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
• Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?